BMO Capital Downgrades St. Jude Medical On 'Less Compelling' Risk/Reward
In a report published Thursday, BMO Capital Markets analyst Joanne Wuensch downgraded the rating on St. Jude Medical, Inc. (NYSE: STJ) from Outperform to Market Perform, while raising the price target from $80 to $81.
St. Jude reported its 2Q15 results ahead of expectations. The company raised its 2015 guidance of revenue growth to 4-6 percent ex-FX, from 4-5 percent ex-FX, and of EPS to $3.96-$4.00, from $3.92-$3.97.
Referring to the company’s acquisition of Thoratec Corporation (NASDAQ: THOR), analyst Joanne Wuensch said, “We do like this transaction, as it builds the company’s heart failure franchise, further minimizes its reliance on the lower-growth CRM market, and solidly moves the revenue growth rate of the company into the mid- to high-single-digit range.” Wuensch expects the Thoratec acquisition for $3.4 billion to be accretive to 2016 by ~$0.15, or ~3 percent.
In the report BMO Capital Markets noted reasons for not expecting an outperformance as:
- The growth drivers are better understood
- Having acquired Thoratec recently, St. Jude is unlikely to be a near-term acquisition candidate
- “The concerns regarding competitive quadripolar leads is proving unfounded (CRM sales were down 1% ex-FX in 2Q15, in line with the market growth rate).”
- The company’s shares are up 18 percent year-to-date, versus a 3 percent rise in the S&P 500, and 14 percent over the past 12 months, versus 7 percent for the S&P 500.
The EPS estimates for 2015 and 2016 have been raised from $3.95 to $3.99 and from $4.26 to $4.29, respectively.
Latest Ratings for STJ
|Jul 2016||Leerink Swann||Downgrades||Outperform||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.